Efficacy and safety of intravenous cyclophosphamide pulse therapy with oral prednisolone in the treatment of interstitial lung disease with systemic sclerosis: 4-year follow-up

Modern Rheumatology

Volumn 21, Issue 3, 2011, Pages 296-301

  Tochimoto, Akiko ^a   Kawaguchi, Yasushi ^a   Hara, Masako ^a   Tateishi, Mutsuto ^a   Fukasawa, Chikako ^a   Takagi, Kae ^a   Nishimagi, Emi ^a   Ota, Yuko ^a   Katsumata, Yasuhiro ^a   Gono, Takahisa ^a   Tanaka, Eiichi ^a   Yamanaka, Hisashi ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Cyclophosphamide; Interstitial lung disease; Prednisolone; Systemic sclerosis

Indexed keywords

CYCLOPHOSPHAMIDE; PREDNISOLONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG PULSE THERAPY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INTERSTITIAL LUNG DISEASE; MAINTENANCE THERAPY; MALE; MYOCARDITIS; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS; TREATMENT RESPONSE; VIRAL INFECTIOUS MYOCARDITIS;

ADMINISTRATION, ORAL; ADULT; AGED; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; PREDNISOLONE; PROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME;

EID: 79960118144     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-010-0403-6     Document Type: Article

References (19)

1. GS Cheema FP Quismorio Jr 2001 Interstitial lung disease in systemic sclerosis Curr Opin Pulm Med 7 5 283 290 11584177 10.1097/00063198-200109000- 00006 1:STN:280:DC%2BD3MrjsFWitw%3D%3D (Pubitemid 32929683)
2. RM Silver JH Warrick MB Kinsella LS Staudt MH Baumann C Strange 1993 Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease J Rheumatol 20 5 838 844 8336309 1:STN:280:DyaK3szivFKktA%3D%3D (Pubitemid 23158478)
3. VD Steen JK Lanz Jr C Conte GR Owens TA Medsger Jr 1994 Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study Arthritis Rheum 37 9 1290 1296 7945491 10.1002/art.1780370904 1:STN:280:DyaK2M%2Fjt1ansg%3D%3D (Pubitemid 24320745)
4. AU Wells P Cullinan DM Hansell MB Rubens CM Black AJ Newman-Taylor RM Du Bois 1994 Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis Am J Respir Crit Care Med 149 6 1583 1590 8004317 1:STN:280:DyaK2c3nt1OgtA%3D%3D (Pubitemid 24175979)
5. DK Vallance JP Lynch 3rd WJ McCune 1995 Immunosuppressive treatment of the pulmonary manifestations of progressive systemic sclerosis Curr Opin Rheumatol 7 3 174 182 7612408 10.1097/00002281-199505000-00004 1:STN:280:DyaK2Mzjs1yktQ%3D%3D
6. A Schnabel M Reuter WL Gross 1998 Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases Arthritis Rheum 41 7 1215 1220 9663478 10.1002/1529-0131(199807)41:7<1215:: AID-ART11>3.0.CO;2-Y 1:CAS:528:DyaK1cXkslWjtLo%3D (Pubitemid 28313423)
7. G Varai L Earle SA Jimenez RM Steiner J Varga 1998 A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease J Rheumatol 25 7 1325 1329 9676764 1:CAS:528:DyaK1cXkslWjsLw%3D (Pubitemid 28312350)
8. SN Liossis A Bounas AP Andonopoulos 2006 Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease Rheumatology (Oxford) 45 8 1005 1008 10.1093/rheumatology/kei211 1:CAS:528:DC%2BD28Xotl2ku7w%3D (Pubitemid 44283057)
9. H Tsukamoto K Nagafuji T Horiuchi T Miyamoto K Aoki K Takase H Henzan D Himeji T Koyama K Miyake, et al. 2006 A phase I-II trial of autologous peripheral blood stem cell transplantation in the treatment of refractory autoimmune disease Ann Rheum Dis 65 4 508 514 16126798 10.1136/ard.2005.037879 1:STN:280:DC%2BD287ktFGqtA%3D%3D
10. B White WC Moore FM Wigley HQ Xiao RA Wise 2000 Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis Ann Intern Med 132 12 947 954 10858177 1:CAS:528:DC%2BD3cXkslylsb8%3D (Pubitemid 30397594)
11. B Griffiths S Miles H Moss R Robertson D Veale P Emery 2002 Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function J Rheumatol 29 11 2371 2378 12415594 1:CAS:528:DC%2BD38XptVGgt7s%3D (Pubitemid 35266028)
12. P Airo E Danieli G Parrinello CM Antonioli I Cavazzana P Toniati F Franceschini R Cattaneo 2004 Intravenous cyclophosphamide therapy for systemic sclerosis. A single-center experience and review of the literature with pooled analysis of lung function test results Clin Exp Rheumatol 22 5 573 578 15485010 1:STN:280:DC%2BD2crhsVOmtg%3D%3D (Pubitemid 39302934)
13. DP Tashkin R Elashoff PJ Clements J Goldin MD Roth DE Furst E Arriola R Silver C Strange M Bolster, et al. 2006 Cyclophosphamide versus placebo in scleroderma lung disease N Engl J Med 354 25 2655 2666 16790698 10.1056/NEJMoa055120 1:CAS:528:DC%2BD28XmtFSgtLs%3D
14. O Nadashkevich P Davis M Fritzler W Kovalenko 2006 A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis Clin Rheumatol 25 2 205 212 16228107 10.1007/s10067-005-1157-y 1:STN:280:DC%2BD283ivFOjug%3D%3D (Pubitemid 43372319)
15. RK Hoyles RW Ellis J Wellsbury B Lees P Newlands NS Goh C Roberts S Desai AL Herrick NJ McHugh, et al. 2006 A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma Arthritis Rheum 54 12 3962 3970 17133610 10.1002/art.22204 1:CAS:528:DC%2BD2sXktlalug%3D%3D (Pubitemid 44955900)
16. O Kowal-Bielecka R Landewe J Avouac S Chwiesko I Miniati L Czirjak P Clements C Denton D Farge K Fligelstone, et al. 2009 EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR) Ann Rheum Dis 68 5 620 628 19147617 10.1136/ard.2008.096677 1:STN:280:DC%2BD1M3ns1ejsg%3D%3D
17. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980,23(5):581-90.
18. P Clements P Lachenbruch J Siebold B White S Weiner R Martin A Weinstein M Weisman M Mayes D Collier 1995 Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis J Rheumatol 22 7 1281 1285 7562759 1:STN:280:DyaK28%2FlslarsQ%3D%3D
19. DP Tashkin R Elashoff PJ Clements MD Roth DE Furst RM Silver J Goldin E Arriola C Strange MB Bolster, et al. 2007 Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease Am J Respir Crit Care Med 176 10 1026 1034 17717203 10.1164/rccm.200702-326OC 1:CAS:528:DC%2BD2sXhsVekt7%2FN (Pubitemid 350127847)